Unique structure of ozoralizumab, a trivalent anti-TNFα NANOBODY® compound, offers the potential advantage of mitigating the risk of immune complex-induced inflammation by Masanao Kyuuma, Ayaka Kaku, Chiemi Mishima-Tsumagari, Bunichiro Ogawa, Mayumi Endo, Yunoshin Tamura, Kei-ichiro Ishikura, Masashi Mima, Yutaka Nakanishi, Yasuyuki Fujii

Get full text